Pharming Net Debt To E B I T D A from 2010 to 2025

PHAR Stock  USD 8.68  0.14  1.64%   
Pharming Group Net Debt To EBITDA yearly trend continues to be relatively stable with very little volatility. Net Debt To EBITDA is likely to grow to 10.51 this year. Net Debt To EBITDA is a leverage ratio that indicates a company's ability to pay off its incurred debt. It compares a company's net debt (total debt minus cash) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). View All Fundamentals
 
Net Debt To EBITDA  
First Reported
2010-12-31
Previous Quarter
10.01
Current Value
10.51
Quarterly Volatility
5.4189991
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Pharming Group financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pharming Group's main balance sheet or income statement drivers, such as Depreciation And Amortization of 19.2 M, Interest Expense of 6.4 M or Selling And Marketing Expenses of 7.4 M, as well as many indicators such as Price To Sales Ratio of 4.16, Dividend Yield of 0.0 or PTB Ratio of 3.92. Pharming financial statements analysis is a perfect complement when working with Pharming Group Valuation or Volatility modules.
  
Check out the analysis of Pharming Group Correlation against competitors.

Latest Pharming Group's Net Debt To E B I T D A Growth Pattern

Below is the plot of the Net Debt To E B I T D A of Pharming Group NV over the last few years. It is a leverage ratio that indicates a company's ability to pay off its incurred debt. It compares a company's net debt (total debt minus cash) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). Pharming Group's Net Debt To EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pharming Group's overall financial position and show how it may be relating to other accounts over time.
Net Debt To E B I T D A10 Years Trend
Slightly volatile
   Net Debt To E B I T D A   
       Timeline  

Pharming Net Debt To E B I T D A Regression Statistics

Arithmetic Mean1.15
Geometric Mean0.99
Coefficient Of Variation471.37
Mean Deviation3.55
Median0.02
Standard Deviation5.42
Sample Variance29.37
Range21.7792
R-Value0.57
Mean Square Error21.16
R-Squared0.33
Significance0.02
Slope0.65
Total Sum of Squares440.48

Pharming Net Debt To E B I T D A History

2025 10.51
2024 10.01
2023 11.12
2022 -1.21
2021 -0.62
2020 -0.47
2019 -0.23

About Pharming Group Financial Statements

Pharming Group shareholders use historical fundamental indicators, such as Net Debt To E B I T D A, to determine how well the company is positioned to perform in the future. Although Pharming Group investors may analyze each financial statement separately, they are all interrelated. The changes in Pharming Group's assets and liabilities, for example, are also reflected in the revenues and expenses on on Pharming Group's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Net Debt To EBITDA 10.01  10.51 

Additional Tools for Pharming Stock Analysis

When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.